1. Home
  2. JMIA vs PHAT Comparison

JMIA vs PHAT Comparison

Compare JMIA & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Jumia Technologies AG each representing two

JMIA

Jumia Technologies AG each representing two

HOLD

Current Price

$6.93

Market Cap

862.0M

ML Signal

HOLD

Logo Phathom Pharmaceuticals Inc.

PHAT

Phathom Pharmaceuticals Inc.

HOLD

Current Price

$11.33

Market Cap

894.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JMIA
PHAT
Founded
2012
2018
Country
Germany
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
862.0M
894.0M
IPO Year
2018
2019

Fundamental Metrics

Financial Performance
Metric
JMIA
PHAT
Price
$6.93
$11.33
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
6
Target Price
$16.75
$19.83
AVG Volume (30 Days)
2.7M
1.3M
Earning Date
05-07-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
42.72
EPS
N/A
N/A
Revenue
N/A
$175,110,000.00
Revenue This Year
$22.18
$93.04
Revenue Next Year
$23.26
$58.91
P/E Ratio
N/A
N/A
Revenue Growth
N/A
216.93
52 Week Low
$3.02
$3.92
52 Week High
$14.72
$18.31

Technical Indicators

Market Signals
Indicator
JMIA
PHAT
Relative Strength Index (RSI) 45.23 43.75
Support Level $6.70 $11.04
Resistance Level $9.49 $12.83
Average True Range (ATR) 0.55 0.73
MACD -0.05 -0.13
Stochastic Oscillator 12.48 8.04

Price Performance

Historical Comparison
JMIA
PHAT

About JMIA Jumia Technologies AG each representing two

Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace that connects sellers with consumers. The logistics services of the company enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. The company generates revenue from first-party sales, third-party sales, marketing and advertising, and the provision of other services. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: